Vertex Pharmaceuticals (VRTX) Change in Intangibles (2023 - 2024)
Vertex Pharmaceuticals (VRTX) posted quarterly Change in Intangibles of $375.4 million for Q4 2024, up 547.24% year-over-year from $58.0 million in Q1 2024, and up 4975.32% quarter-over-quarter from -$7.7 million in Q2 2024.
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) Change in Intangibles (2023 - 2024) Analysis & Trends
Vertex Pharmaceuticals' Change in Intangibles history runs 2 years deep, the most recent figure standing at $375.4 million for Q4 2024.
- In Q4 2024, Change in Intangibles rose 547.24% year-over-year to $375.4 million; the TTM figure through Sep 2025 stood at $375.4 million (up 389.44% YoY), while the FY2024 annual figure was $187.7 million, up 223.62% from the prior year.
- Change in Intangibles for Q4 2024 stood at $375.4 million, up from -$7.7 million in the prior quarter.
- The five-year high for Change in Intangibles was $375.4 million in Q4 2024, with the low at -$180.0 million in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | - |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.60 Bn | 21.07 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 375.40 Mn |
| Jun 30, 2024 | -7.70 Mn |
| Mar 31, 2024 | -180.00 Mn |
| Dec 31, 2023 | 58.00 Mn |